June 29, 2020

New radiotherapy method improves long-term survival

OICR Investigator-led phase II clinical trial shows long-term advantage of ablative therapy for patients with multiple tumours. Technology enters phase III clinical testing.

Varian TruBeam®
© 2010 Varian Medical Systems International AG, All Rights Reserved

For a long time, if a cancer had spread to another part of a patient’s body, it was thought to be incurable. Dr. David Palma and collaborators are challenging this notion.

In the phase II SABR-COMET clinical trial, Palma and colleagues evaluated the long-term effects of a modern type of radiotherapy, called stereotactic ablative radiotherapy (SABR), on individuals with cancers that have spread to a few organs. The results from the trial, which were recently published in the Journal of Clinical Oncology, show that SABR can extend the lives of these patients by a median of 22 months with an improvement in five-year survival of 25 per cent.

Continue reading – New radiotherapy method improves long-term survival